EVO
Evotec SENASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
1.00
P/S
1.06
EV/EBITDA
-11.82
DCF Value
$-3.98
FCF Yield
-11.2%
Div Yield
0.0%
Margins & Returns
Gross Margin
10.8%
Operating Margin
-11.3%
Net Margin
-21.0%
ROE
-18.1%
ROA
-10.8%
ROIC
-5.7%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $163.9M | $-43.1M | $-0.12 |
| Q2 2025 | $171.2M | $-43.5M | $-0.12 |
| Q1 2025 | $200.0M | $-31.6M | $-0.09 |
| Q4 2024 | $221.2M | $-40.8M | $-0.11 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
DE
Exchange
NASDAQ
Beta
1.24
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.